High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study.
Fiche publication
Date publication
mai 2022
Journal
European journal of preventive cardiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Silbernagel G, Duarte K, Sadiku S, Fauler G, März W, Schmieder RE, Jardine AG, Massy ZA, Girerd N, Fellström B, Rossignol P, Scharnagl H, Zannad F
Lien Pubmed
Résumé
Statin treatment did not reduce the risk of cardiovascular events in haemodialysis patients in the 4D and AURORA trials. Post hoc analyses in the 4D study suggested that high cholesterol absorption was associated with increased cardiovascular risk and that atorvastatin would reduce cardiovascular risk in haemodialysis patients with low cholesterol absorption but not in those with high cholesterol absorption.
Mots clés
Cardiovascular risk, Cholestanol, Cholesterol, Cholesterol absorption, Hemodialysis, Randomized controlled trial, Rosuvastatin
Référence
Eur J Prev Cardiol. 2022 May 4;: